Our core content on Lung conditions and related factsheets has been translated to a number of other languages.
For more languages explore all available Factsheet translations.
Volunteer as a translator or learn how to translate using Chrome, Firefox or Edge browsers.
European Lung Foundation
Our core content on Lung conditions and related factsheets has been translated to a number of other languages by our volunteer team.
For more languages explore all available Factsheet translations.
Volunteer as a translator or learn how to translate using Chrome, Firefox or Edge browsers.
Non-small-cell lung cancer (NSCLC), the most common type of lung cancer, is the leading cause of cancer deaths worldwide and few drug treatments exist.
The research, published in the journal Oncogene, investigated the effectiveness of breast cancer drugs called PARP inhibitors.
The findings revealed that the drugs killed cancerous cells and left the healthy ones intact, in up to half of NSCLC tumours.
Study author Dr Chris Lord said: “This study suggests that PARP inhibitors, treatments already in clinical trials to treat breast and ovarian cancer, could also be a promising treatment for patients with certain forms of lung cancer.
Sign up to our free monthly newsletter to get the latest information and research news on lung conditions, plus views from experts and patients! You can unsubscribe at any time.
ELF is a non-profit organisation registered as a UK company (VAT no. GB 115 0027 74) and charity (no. 1118930).
Our Brussels office enterprise number is 0738.383.695
European Lung Foundation's TR ID number in the Transparency Register is: 094039644810-79